Inovio sells off animal health assets to zero in on vaccines

In order to remain dedicated to its main cash cow--vaccines--Inovio ($INO) is making some changes. This week, the company's VGX Animal Health subsidiary sold its animal health assets--including an exclusive license with Inovio for animal DNA vaccines--to South Korea's Plumbline Life Sciences. Inovio will instead stay "sharply focused" on the company's immunotherapy products, President and CEO Dr. J. Joseph Kim said in a statement. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.